Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HEDGE-A

Financiado

HEDGE-A: High cell density engineering for the production of recombinant adeno-a...

HEDGE-A: High cell density engineering for the production of recombinant adeno-associated virus (rAAV). HEDGE-A will address one of the current main challenges of biopharmaceutical production: The scalability of the recombinant adeno-associated virus (rAAV) production process. Big Data approaches like transcriptomic and proteomic an... ver más

30/04/2026

TECHNICAL UNIVERSI...

215K€

Presupuesto del proyecto: 215K€

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-27

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

TECHNICAL UNIVERSITY OF DENM...

214.93K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EXPEDITE EXPanding AAV gene therapy by EDITing 2M€ Cerrado

CPP2021-008999 Nuevas terapias genéticas basadas en inteínas para el síndro... 774K€ Cerrado

PCIN-2015-125 MINICELL 200K€ Cerrado

MeDiSyn Scalable Microbial Metabolite Discovery Through Synthetic Bi... 1M€ Cerrado

RTC-2016-4603-1 Escalado del suministro y estudios de eficacia del indolocar... 611K€ Cerrado

PLEC2023-010243 Herramientas diagnósticas, pronósticas y terapéuticas 539K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2023-03-27
Fecha Fin: 2026-04-30

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 215K€

Descripción del proyecto HEDGE-A will address one of the current main challenges of biopharmaceutical production: The scalability of the recombinant adeno-associated virus (rAAV) production process. Big Data approaches like transcriptomic and proteomic analyses will be used together with synthetic biology tools to engineer cell cultures and improve rAAV production. The objectives of HEDGE-A are to design (1) a suitable cell platform to sustain transfection at high cell densities and (2) a scalable upstream bioprocess to improve rAAV biomanufacturing. Access to gene therapy is currently extremely limited due to the high cost of producing rAAVs, leading to expensive treatments and making it virtually inaccessible for the general population or even for diseases requiring high dosage. The main limitation is the poor scalability of the current rAAV production process. HEDGE-A will delve into the molecular limitations of the cellular platform and provide a solution to reduce costs, increase titers and help rAAV-based gene therapies reach the wider population. A cost-effective production process for rAAVs will have a high impact in EU competitiveness as it will open the market for countless gene and cell therapies that are currently non-viable due to the required titers to reach clinical trials. HEDGE-A will present the perfect opportunity for the applicant to join a cutting-edge working environment to fulfil his potential in cell engineering and bioprocess development. The host centre, DTU (Copenhagen) is a leading expert in the field and can provide the essential network to undertake a project like HEDGE-A, bridging academic research and its industrial application.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores